Novo Nordisk to invest £115m in Oxford’s research
Danish pharmaceutical firm Novo Nordisk partners Oxford University on ten-year collaboration to tackle type-2 diabetes.
Danish pharmaceutical firm Novo Nordisk partners Oxford University on ten-year collaboration to tackle type-2 diabetes.
Oxford University Innovation launches 24 companies in 2016 with a combined £52.6m in early stage funding, setting a new record in spinout generation for the UK and Europe.
OxSonics, an Oxford University spinout established in 2013 to develop ultrasound therapeutics, has secured £9.4m in series B equity financing, bringing its total external fundraising to £14.2m.
Handheld DNA sequencer developer Oxford Nanopore secures £100m in funding, valuing the company at £1.25bn.
Biomarker spinout Oxford Biodynamics holds successful flotation on AIM.
Oxford Sciences Innovation's latest fundraising rounds off year which saw Oxford University Innovation launch 22 new spinout companies.
Atopix Therapeutics Limited, a UK biotechnology company with roots back to Oxford University, has been acquired by Italian pharmaceutical firm Chiesi Farmaceutici Spa.
Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research.
Oxford spinout Argonaut Therapeutics is developing cancer drugs which reprogram cancer cells to undergo the body’s natural process of cell death, shrinking tumours. The company will focus on treatments for colorectal cancer and lymphoma.
Thirty-five Oxford projects received £4.6m in funding from proof-of-concept and seed funds managed by Oxford University Innovation in the last financial year.